Are you an EPFL student looking for a semester project?
Work with us on data science and visualisation projects, and deploy your project as an app on top of Graph Search.
Concept
Remdesivir
Summary
Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. During the COVID19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID19 in numerous countries.
Remdesivir was originally developed to treat hepatitis C, and was subsequently investigated for Ebola virus disease and Marburg virus infections before being studied as a post-infection treatment for COVID19.
Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.
The most common side effect in healthy volunteers is raised blood levels of liver enzymes. The most common side effect in people with COVID19 is nausea. Side effects may include liver inflammation and an infusion-related reaction with nausea, low blood pressure, and sweating.
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
In the European Union, remdesivir is indicated for the treatment of coronavirus disease 2019 (COVID19) in adults and adolescents (aged twelve years and older with body weight at least ) with pneumonia requiring supplemental oxygen and for adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID19.
In the United States, remdesivir is indicated for the treatment of COVID19 in people 28 days of age and older and weighing at least who are hospitalized; or not hospitalized and have mild-to-moderate COVID19, and are at high risk for progression to severe COVID19, including hospitalization or death.
In November 2020, the FDA issued an emergency use authorization (EUA) for the combination of baricitinib with remdesivir, for the treatment of suspected or laboratory confirmed COVID19 in hospitalized people two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Official source
About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.